- Home
- IDN vs INZY Comparison
IDN vs INZY Comparison
Compare IDN & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- INZY
- Stock Information
- Founded
- IDN 1994
- INZY 2015
- Country
- IDN United States
- INZY United States
- Employees
- IDN N/A
- INZY N/A
- Industry
- IDN Computer Software: Prepackaged Software
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- INZY Health Care
- Exchange
- IDN Nasdaq
- INZY Nasdaq
- Market Cap
- IDN 59.5M
- INZY 64.9M
- IPO Year
- IDN 1999
- INZY 2020
- Fundamental
- Price
- IDN $5.09
- INZY $3.97
- Analyst Decision
- IDN Strong Buy
- INZY Buy
- Analyst Count
- IDN 3
- INZY 9
- Target Price
- IDN $5.83
- INZY $15.22
- AVG Volume (30 Days)
- IDN 526.6K
- INZY 5.3M
- Earning Date
- IDN 05-13-2025
- INZY 05-14-2025
- Dividend Yield
- IDN N/A
- INZY N/A
- EPS Growth
- IDN N/A
- INZY N/A
- EPS
- IDN N/A
- INZY N/A
- Revenue
- IDN $20,211,000.00
- INZY N/A
- Revenue This Year
- IDN $8.56
- INZY N/A
- Revenue Next Year
- IDN $9.64
- INZY N/A
- P/E Ratio
- IDN N/A
- INZY N/A
- Revenue Growth
- IDN 4.55
- INZY N/A
- 52 Week Low
- IDN $1.92
- INZY $0.72
- 52 Week High
- IDN $5.46
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- IDN 76.01
- INZY 85.93
- Support Level
- IDN $3.67
- INZY $3.94
- Resistance Level
- IDN $5.46
- INZY $3.97
- Average True Range (ATR)
- IDN 0.51
- INZY 0.08
- MACD
- IDN 0.18
- INZY 0.12
- Stochastic Oscillator
- IDN 86.25
- INZY 99.32
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.